{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":24,"n_cols":5,"rows_kept":24,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[17,2,17,3],[18,2,18,3],[21,2,21,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910899893503321"]
[null,null,"Autore",null,"Nandave Mukesh"]
[null,null,"Titolo",null,"Angiotensin-converting Enzyme Inhibitors vs. Angiotensin Receptor Blockers : A Critical Analysis of Antihypertensive Strategies: A Machine-Generated Literature Overview / / edited by Mukesh Nandave"]
[null,null,"Pubbl/distr/stampa",null,"Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2024"]
[null,null,"ISBN",null,"981-9773-80-6"]
[null,null,"Edizione",null,"[1st ed. 2024.]"]
[null,null,"Descrizione fisica",null,"1 online resource (609 pages)"]
[null,null,"Disciplina",null,"616.1061"]
[null,null,"Soggetti",null,"Pharmacology"]
[{"$nulls":4},"Pharmacovigilance"]
[{"$nulls":4},"Medicine - Research"]
[{"$nulls":4},"Biology - Research"]
[{"$nulls":4},"Clinical biochemistry"]
[{"$nulls":4},"Therapeutics"]
[{"$nulls":4},"Drug Safety and Pharmacovigilance"]
[{"$nulls":4},"Biomedical Research"]
[{"$nulls":4},"Medical Biochemistry"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Nota di bibliografia","Includes bibliographical references."]
[null,null,"Nota di contenuto",null,"Chapter 1_ Introduction of the renin-angiotensin-aldosterone system (RAAS) -- Chapter 2_ Role of anti-hypertensive agents in cardiovascular disorders -- Chapter 3_ (ACE) Angiotensin-converting enzyme inhibitors: Preferred RAAS inhibitor in high-risk patients as compared to angiotensin receptor blockers (ARBs) -- Chapter 4_ Role of (ACE) angiotensin-converting enzyme inhibitors in transforming renin–angiotensin system -- Chapter 5_ The effect of (ACE) Angiotensin-converting enzyme inhibitors vs angiotensin receptor blockers on insulin resistance in hypertensive patients -- Chapter 6_ Role of (ACE) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in acute heart failure -- Chapter 7_ Immunomodulator activity of (ACE) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertensive patients -- Chapter 8_ Role of (ACE) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in peripheral artery disease -- Chapter 9_ Role of (ACE) Angiotensin-converting enzyme inhibitors and angiotensin receptor "]
[{"$nulls":4},"blockers in covid-19 patients -- Chapter 10_ Recent trends in the management of hypertension through RAAS inhibition."]
[null,null,null,"Sommario/riassunto","The auto-summaries have been generated by a recursive clustering algorithm via the Dimensions Auto-summarizer by Digital Science handled by Subject Matter Experts and the editor(s) of this book. The editor(s) of this book selected which SN content should be auto-summarized and decided its order of appearance. Please be aware that these are extractive auto-summaries, which consist of original sentences, but are not representative of its original paper, since we do not show the full length of the publication. Please note that only published SN content is represented here, and that machine-generated books are still at an experimental stage."]